Welcome to our dedicated page for Insulet news (Ticker: PODD), a resource for investors and traders seeking the latest updates and insights on Insulet stock.
Insulet Corporation reports news on its Omnipod product platform for diabetes care, including the Omnipod Insulin Management System and Omnipod 5 Automated Insulin Delivery System. The company’s tubeless disposable Pods provide up to three days of insulin delivery, while Omnipod 5 integrates with continuous glucose monitors and can be controlled through a compatible smartphone in the U.S. or through the Omnipod 5 Controller.
Recurring Insulet developments include quarterly results, Omnipod revenue trends, sensor-connectivity updates, clinical evidence for automated insulin delivery, and research involving fully closed-loop systems for type 2 diabetes. Company updates also cover medical device corrections, product quality actions, executive appointments, conference presentations, and the use of Omnipod technology for non-insulin subcutaneous drug delivery.
Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, has released its 2024 Sustainability Report highlighting significant ESG achievements. The company met 11% of its global electricity needs with renewable energy and installed over 5,700 solar panels at its Malaysia facility, covering 21% of the facility's electricity needs. The facility is designed to achieve GBI and LEED Silver certifications.
Key accomplishments include collecting 7.4 million Pods through global takeback programs and expanding access to Omnipod 5 internationally through integration with Abbott's FreeStyle Libre 2 Plus and Dexcom G7 sensors. The company also launched the Omnipod 5 App for iPhone and introduced "Insulet for Good," a global corporate giving program that exceeded employee engagement goals.
Insulet (NASDAQ: PODD) has appointed Ashley McEvoy as President and CEO, effective immediately, replacing Jim Hollingshead who will cease employment on April 28, 2025. McEvoy brings nearly three decades of healthcare leadership experience, previously serving as Executive Vice President and Worldwide Chairman of Johnson & Johnson's MedTech business.
Under Hollingshead's leadership, Insulet launched Omnipod 5, achieving market leadership in type 1 diabetes in the U.S. and Europe, and became first-to-market in Automated Insulin Delivery for type 2 diabetes in the U.S. The company expects to exceed its Q1 2025 revenue guidance and plans to raise full-year 2025 guidance, with details to be announced on May 8, 2025.
Due to the leadership transition, Insulet has postponed its previously scheduled June 5, 2025 Investor Day to a later date.
Insulet (NASDAQ: PODD), the global leader in tubeless insulin pump technology, will release its first quarter 2025 financial results on May 8, 2025, after market close. Management will host a conference call at 4:30 p.m. (Eastern Time).
The company specializes in the Omnipod Insulin Management System, offering a tubeless disposable Pod that provides up to three days of continuous insulin delivery. Their flagship product, the Omnipod 5 Automated Insulin Delivery System, integrates with continuous glucose monitors and can be controlled via smartphone in the U.S. or through the Omnipod 5 Controller.
Insulet (NASDAQ: PODD) announced significant results from its RADIANT study of the Omnipod 5 Automated Insulin Delivery System. The multinational randomized controlled trial evaluated direct transition from multiple daily injections (MDI) to automated insulin delivery in type 1 diabetes patients.
Key findings from the 188-participant study showed:
- Average HbA1c reduction of -0.8% compared to MDI with continuous glucose monitor
- Additional 5.4 hours per day with glucose levels in target range (70-180mg/dL)
- Final average time in range improved to 65% from 39% baseline
- No life-threatening events or severe hypoglycemia reported
The study, conducted across 19 clinical centers in France, UK, and Belgium, included participants aged 4-70 years with HbA1c levels of 7.5% to 11%. Patients using Omnipod 5 with initial HbA1c above 8.0% showed even greater improvement of 1.0% compared to MDI plus CGM.
Insulet (NASDAQ: PODD) has announced the pricing of $450 million in senior unsecured notes due 2033. The notes will carry a 6.50% annual interest rate with maturity on April 1, 2033. The private placement is expected to close on March 20, 2025.
The company estimates net proceeds of approximately $444.4 million after discounts and before offering expenses. The funds will be used to finance the redemption or repurchase of existing 0.375% Convertible Senior Notes due 2026, cover related fees and expenses, and for general corporate purposes. The notes are being offered exclusively to qualified institutional buyers under Rule 144A and non-U.S. persons outside the United States under Regulation S.
Insulet (NASDAQ: PODD), a leader in tubeless insulin pump technology, has announced plans to offer $450 million in senior unsecured notes due 2033 through a private placement. The company intends to use the proceeds, along with cash on hand, to manage its existing 0.375% Convertible Senior Notes due 2026.
Additionally, Insulet plans to amend its Credit Agreement to extend its revolving credit facility maturity from 2028 to 2030 and increase revolving credit commitments by up to $200 million, potentially reaching aggregate commitments of up to $500 million. Both transactions are subject to market conditions and may not proceed as described.
The Notes will be exclusively offered to qualified institutional buyers under Rule 144A and non-U.S. persons outside the United States under Regulation S of the Securities Act of 1933.
Insulet (NASDAQ: PODD) has announced the expansion of its Omnipod 5 Automated Insulin Delivery System to four new international markets. The system is now commercially available in Australia with Dexcom G6 and G7 compatibility, and will soon launch in Belgium, Canada, and Switzerland.
The tubeless insulin delivery system features SmartAdjust™ technology that automatically adjusts insulin delivery every five minutes. In Australia, plans are underway to add Abbott's FreeStyle Libre® 2 Plus compatibility. Belgium will have access to both Abbott's FreeStyle Libre 2 Plus and Dexcom G6/G7 integrations. Canada and Switzerland launches are scheduled for spring, with varying sensor compatibilities.
Additionally, Insulet plans to expand to five more markets including Israel, Saudi Arabia, UAE, Qatar, and Kuwait, with timing to be announced. The company recently added Dexcom G7 integration for Omnipod 5 users in the UK and Netherlands.
Insulet (NASDAQ: PODD) will present results from its multinational RADIANT trial at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in March 2025. The study compared the Omnipod 5 Automated Insulin Delivery System to multiple daily injections in type 1 diabetes patients aged 4-70 years across France, UK, and Belgium.
The RADIANT trial marks two significant firsts: it's the first randomized controlled trial examining direct transition from multiple daily injections to an automated insulin delivery system, and the first to assess an AID system with Abbott FreeStyle Libre 2 sensors. Results will be presented at a symposium featuring renowned medical experts, including Dr. Emma Wilmot, Dr. Chantal Mathieu, and Dr. Brynn Marks.
The conference will showcase 11 presentations and posters on Omnipod 5 and Omnipod DASH systems, covering various aspects including real-world outcomes, comparative studies, and specific use cases in both Type 1 and Type 2 diabetes patients.
Insulet (NASDAQ: PODD), the global leader in tubeless insulin pump technology, has announced its upcoming Investor Day scheduled for June 5, 2025 at their global headquarters in Acton, Massachusetts.
The event, running from 10:00 a.m. to 1:30 p.m. (ET), will feature presentations by President and CEO Jim Hollingshead, Executive Leadership Team members, and independent experts. The agenda will cover:
- Comprehensive overview of the Omnipod® 5 platform
- Strategic priorities and market opportunities
- Growth drivers and innovation roadmap
- Financial outlook
While in-person attendance is by invitation only, investors can join via live webcast through the company's Investor Relations website. The webcast replay and presentations will be available post-event at investors.insulet.com under 'Events and Presentations'.